UCL Institute of Cardiovascular Science
- Myocardial disease
- Structural heart disease
- Vascular disease
- Cardiovascular genetics
- Regenerative medicine
- Genetic epidemiology and translational cardiovascular genomics
- Preventions and outcomes
- National centre for cardiovascular preventions and outcomes
- Clinical epidemiology of cardiovascular disease
- Cardiovascular risk - obesity research
- News & events
- For staff
- Contact us
Clinical epidemiology of cardiovascular disease
Professor Hemingway's research focuses on cardiovascular disease in populations. The work of his group aims to investigate the aetiology and prognosis of specific coronary phenotypes – rather than the aggregate of ‘CHD’ which may conceal important associations. There are three broad approaches to this work: establishing novel clinical cohorts, exploitation of linked electronic health records and methods development in prognosis research.
Our research is funded by the Wellcome Trust, Medical Research Council, National Institute of Health Research and the European Commission Framework Programme 7.
Key research activities
The Farr Institute of Health Informatics Research is comprised of four nodes distributed across the UK and led from UCL, University of Manchester, Swansea University, and the University of Dundee. With a £17.5m-research award from a 10-funder consortium, plus additional £20m-capital funds from the Medical Research Council, the Farr Institute aims to deliver high-quality, cutting-edge research linking electronic health data with other forms of research and routinely collected data, as well as build capacity in health informatics research. The Farr Institute aims to provide the physical and electronic infrastructure to facilitate collaboration across the four nodes, support their safe use of patient and research data for medical research, and enable partnerships by providing a physical structure to co-locate NHS organizations, industry, and other UK academic centres.
We are establishing a
multi-centre cohort phenotyping and genotyping people with suspected and
confirmed stable coronary disease, with follow up for coronary endpoints. This
will allow a range of translational research questions to be addressed under
different study designs appropriate to studying causes of disease onset
(case-control), disease progression (cohort) and pharmacogenetic effects.
CALIBER has linked differentiated acute coronary syndrome endpoints from
MINAP (Myocardial Ischaemia National Audit Project) to the primary care record
in GPRD (General Practice Research Database). This allows longitudinal
investigation of risk and care, before, during and after and event. Linkages of MINAP to large investigator led
cohorts, such as the UK Biobank, is planned.
The MRC funded PROGRESS Partnership is an international, interdisciplinary collaboration developing understanding in research into prognostic factors, risk prediction models and predictors of differential treatment response (stratified medicine).